Seer, Inc. (SEER) - Q2 2024 10-Q Summary
Business Context and Reporting Period
Seer, Inc. is a life sciences company developing the Proteograph Product Suite, an integrated solution for proteomics research. This report covers the quarterly period ended June 30, 2024. The company is classified as a smaller reporting company and a non-accelerated filer. It operates with a dual-class share structure, where Class B shares held by founders and early investors carry 10 votes per share, controlling approximately 41.3% of voting power as of August 6, 2024.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $3.07 million | $4.01 million | $6.14 million | $8.06 million |
| Gross Profit | $1.73 million | $2.28 million | $3.09 million | $4.35 million |
| Net Loss | $(22.85) million | $(23.43) million | $(43.53) million | $(47.39) million |
| Operating Expenses | $28.83 million | $30.22 million | $55.38 million | $59.74 million |
| Cash & Investments | $344.6 million (as of June 30, 2024) | |||
| Accumulated Deficit | $(349.3) million (as of June 30, 2024) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 23% year-over-year in Q2 and 24% year-over-year for the six-month period. The decline was primarily driven by a significant reduction in related party revenue (down 57% in Q2) and the absence of grant revenue recognized in the current period.
- Expense Reduction: Operating expenses decreased slightly, with Research and Development (R&D) down 10% in Q2 due to lower headcount and reduced stock-based compensation. Selling, General, and Administrative (SG&A) expenses remained flat.
- Share Repurchases: The company initiated a $25.0 million share repurchase program in May 2024. During Q2, it repurchased approximately 2.03 million shares for $3.75 million.
- Inventory Build: Inventory increased to $7.58 million from $4.49 million at year-end 2023, reflecting a buildup of finished goods.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes current cash, cash equivalents, and short-term investments ($344.6 million) are sufficient to fund operations for at least the next 12 months. The company expects to continue incurring significant operating losses in the near term.
- Commercialization: The company is in the early stages of commercializing the Proteograph Product Suite. Success depends on broad scientific and market acceptance, which remains uncertain.
- Key Risks:
- Customer Concentration: A related party, PrognomiQ, Inc., accounted for 19% of Q2 revenue and 25% of YTD revenue.
- Profitability: The company has a history of net losses and may never achieve profitability.
- Regulatory: Products are currently labeled for research use only (RUO). Future expansion into clinical diagnostics would require FDA clearance, which is costly and uncertain.
- Intellectual Property: Reliance on licensed patents from third parties (e.g., Brigham and Women's Hospital) and potential litigation regarding inventorship.
Investor Verification Checklist
- Verify the sustainability of revenue from the related party, PrognomiQ, Inc., and the impact of its potential reduction on future financials.
- Assess the timeline and capital requirements for the commercialization of the Proteograph Product Suite given the current revenue decline.
- Review the status of the $25.0 million share repurchase program and its impact on remaining liquidity.
- Monitor the outcome of the inventorship lawsuit filed by Giulio Caracciolo regarding patents licensed from Brigham and Women's Hospital.
- Confirm the company's ability to maintain Nasdaq listing requirements given the multi-class share structure and stock price volatility.